Project Grant R21AI193834
- Federal Grant Award Summary Emory University received a $922,840 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 2, 2026 through January 31, 2031. The award supports research on Inducible Hepatic-Associated Lymphoid Tissue (iHALT) and the generation and maintenance of long-lived plasma cells during hepatotropic viral infection. The research utilizes a rodent...
- Federal Grant Award Summary Emory University received a $778,829 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective June 2, 2025, through May 31, 2030. The award funds a comprehensive research initiative to characterize early-life B-cell and antibody-secreting cell (ASC) development in the human spleen, with particular focus on understanding how naturally occurring plasma...
- Federal Project Grant Award Summary Emory University received a $412,749 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 6, 2026, with a completion date of January 31, 2028. The research project aims to identify and characterize cis-regulatory elements (enhancers) that facilitate precise genetic manipulation of specific B-cell subsets, including memory B cells (MBC) and...
- Federal Grant Award Summary Emory University received a $954,603 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded April 9, 2026, with completion targeted for March 31, 2028. The grant supports development of a novel long-acting injectable nanoparticle formulation encapsulating ALG-001075, a proprietary capsid assembly modulator (CAM) with pan-genotypic antiviral activity...
- Federal Grant Award Summary Emory University received a $909,998 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 5, 2026 through January 31, 2031. The grant supports research characterizing an antiretroviral therapy (ART)-free approach to establishing simian immunodeficiency virus (SIV) reservoirs using broadly neutralizing antibodies (BNAbs) and antibody-like...
- Federal Project Grant Award Summary Emory University's Office of Sponsored Programs received a $430,375 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025, with completion scheduled for July 31, 2027. The award funds investigator-initiated biomedical research examining inter-membrane lipid signaling mechanisms in gram-negative bacteria, specifically focusing on...
- Federal Grant Award Summary Emory University received a $910K Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded May 5, 2026, with completion targeted for April 30, 2031. The grant supports investigator-initiated biomedical research focused on developing an innovative HIV vaccination strategy utilizing DNA-lipid nanoparticle (DNA-LNP) technology to induce durable cellular and...
- Federal Grant Award Summary Emory University received a $711,555 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 13, 2025, through April 30, 2030. The project delivers an integrated research and development framework combining graph neural networks with traditional compartmental models to advance understanding of spatiotemporal transmission dynamics and control...
- Federal Grant Award Summary Emory University received a $160,546 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on September 3, 2025, with a completion date of August 31, 2029. The award supports the development of a novel spatiotemporal machine learning framework designed to establish foundational epidemic models for respiratory infections. This research initiative leverages...
- Federal Grant Award Summary Emory University received a $2,297,892 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 17, 2025, with completion targeted for June 30, 2029. The award funds a four-year research investigation into the mechanisms by which interferon-induced transmembrane proteins (IFITMs) inhibit viral membrane fusion and restrict diverse enveloped viruses...
Emory University's Office of Sponsored Programs received a $273,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective May 8, 2026, through April 30, 2028. The award funds an exploratory research project investigating the role of B cells and antibody responses in virus-induced hepatocellular carcinoma (HCC) using a rodent model of chronic hepaciviral infection. The research aims to establish a physiological disease progression model that mimics natural HCC development and provides insights into cancer immunobiology for translating future immunotherapies against virus-induced HCC. The project delivers research services through experimental investigations using specially engineered mouse models with variable B cell functional defects to elucidate whether antigen-specific B cells, B cell-specific antigen presentation, or immunoglobulin G (IgG) production contribute to viral-induced HCC formation. The research utilizes three mouse strains with distinct B cell characteristics—B1-8I mice with restricted B cell receptor repertoire, MHCIIF/FCD19CRE conditional knockout mice lacking B cell-specific antigen presentation, and AIDCRE mice lacking activation-induced cytidine deaminase—to evaluate mechanisms underlying the relationship between viral persistence, immune response dysfunction, and hepatocellular carcinoma development. The research will be conducted at Emory University's Atlanta, Georgia location.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $273.0k | 5/12/26 |